Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faricimab Treat-and-Extend for Type 3 MNV
NCT07187804Phase 4Not yet recruiting
- Sponsor
- Kim's Eye Hospital
- Start
- Sep 2025
- Primary completion
- Sep 2028
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of faricimab in retinal angiomatous proliferation (RAP), sponsored by Kim's Eye Hospital. Primary endpoint: Central Subfield Thickness at 76 weeks. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
faricimab
03
Conditions
retinal angiomatous proliferation (RAP)
Beyond the preview
Go deeper on NCT07187804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07187804.